Professional background

Professor Payne was appointed as a consultant in clinical oncology at University College Hospital, London in 1997. She trained at St Marys Hospital London Medical School and after qualifying spent some working in general medicine both in London and also in Haiti. She returned to London to train as a clinical oncologist and during this time developed an interest in urological oncology. She has a busy practice specialising in the management of urological malignancies in London where she works within a multidisciplinary team. She is actively involved in clinical research in all these therapeutic areas and has pioneered a programme of high dose-rate brachytherapy for prostate cancer at the UCH site.

Professor Payne's current research interests also include hormone therapy as adjuvant treatment for locally advanced disease, sensitisation of hormones and radiotherapy, maximal androgen blockade, predictive indices for bowel toxicity with radiotherapy, chemotherapy and quality of life and decision-making for men with prostate cancer. She is principal investigator in a number of international multi-centre and local studies. She is a trustee of the Prostate Cancer Research Centre and the chairman of the British Uro-oncology Group (BUG). She also serves on CTAAC, the Prostate Cancer Charter for Action, and the Department of Health Prostate Cancer Advisory Group for the United Kingdom.

Research interests

  • Urological tumours
  • Prostate cancer (special interest)
  • Active surveillance
  • Radiotherapy
  • High dose-rate brachytherapy
  • Chemotherapy
  • Novel agents and clinical trials

Publications

Response of cyclophosphamide-resistant Wegeners granulomatosis to etoposide
De Cruz D, Payne H, Timothy ART, Hughes GRV
Lancet 1992 Vol. 340 pp 425-426

Responses to gamma-interferon of late metastases from renal carcinoma
Sizer B, Payne H, Beeney R
Interferon & Cytokines 1993 - prize winning essay

Routine prophylactic PEG feeding permits more effective chemo-radiotherapy in head & neck cancer
Payne H, Brown R, Blackman G, Tobias JS
British Journal of cancer 1997 Vol 76 (Supp. 1) p39

Does referral for treatment of spinal cord compression occur more frequently on a Friday afternoon?
Brown R.S.D., Rajaram S., Burcombe R.J., Payne H.A.
Brtish Journal of Cancer. 1998,78: 32.

An audit to compare planning target volumes using conventional CT scan grey scale planning and the CT Acqsim system for radical radiotherapy of carcinoma of the prostate.
Power D., Money-Kyrle JF., Allen S., Brown RSD., Payne HA.
B.J.C. 2000, 83 (S1) p53.

Radiotherapy for prevention of hormone-induced gynaecomastia and mammalgia inadvanced prostate cancer treated with stilboestrol.
Brown RSD., Money-Kyrle JF., Payne HA., Duchesne GM.,
B.J.C. 2000,83 (S1) p75.

Anorectal irradiation during radiotherapy for prostate cancer : an assessment using in-vitro dosimetry
Hayne D., Johnson U., D’Souza D., Boulos PB.,Payne HA.
British Journal Cancer 2000, 83 p 46-48

Anorectal irradiation in following pelvic radiotherapy- an asessment using in-vivo dosimetry
Hayne D., Johnson U., D’Souza D., Boulos PB., Payne H.A.
Journal Clinical Oncology 2001 Vol 13 (2) 126-129.

Trends in Colorectal Carcinoma Incidence Mortality and Survival in England and Wales 1971-1999
Brown RSD,. Power D., McCormack M., Hayne D., Payne HA.
Journal Clinical Oncology Vol 13 (S1) 2001

First report of an isolated Jejunal seminoma: - a novel presentation with melaena and iron deficiency anaemia.
Brown RSD, Yassin J, Colville C, Harland SJ, Payne HA.
J Clin Onc 2001 13 (6): 455-457

Trends in Testicular Cancer Incidence, Mortality and Survival in England and Wales 1971-1999.
Power D, Brown R.S.D, Brock C.S., Payne H.A., Majeed A, Babb P.
BJU International (2001) 87: 361-365

Current trends in Colorectal Cancer: Site, Incidence, Mortality and Survival in England and Wales.
Hayne D, Brown RSD, McCormack M, Quinn m, Payne HA, Babb P.
J Clin Onc 2001 13 (6) 448-452

A national audit of chemoradiation practice in head and neck tumours in the United Kingdom
Brown R.S.D, McCormavk M, Melcher L, Payne H.A.
Br J Cancer 2001(S1);85 :62

The effect of deprivation on incidence, mortality and survival for the most common cancers in the United Kingdom
Melcher L, Power D.A, Brown R.S.D, McCormack M,Payne H.A, Babb P, Quinn M.
Br J Cancer 2001(S1);85:62

Anorectal radiotherapy during radiotherapy for carcinoma of the prostate: a comparison of helax predicted and diode measured doses
Hayne D, Johnson U, Brown R.S.D, D’Souza D, Hare C, Boulso P, Payne H.A.
Br J Cancer 2001;85(S1):65

A National audit of chemoradiation practice in the UK
for cervical cancer
M McCormack, AJ Birtle, HA Payne
Clinical Oncology, 2001, 13:319

Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase 1 study
Whitelaw DE, Chang SC, Lees WR, Ripley PM, Payne HA et al
Journal of Urology 2002: 168 (4 Pt 1): 1427- 1432

Amplification of the androgen receptor gene in bone metastases from
hormone-refractory-prostate-cancer
R. S. D. Brown, J. Edwards, A. Dogan, H. Payne, S. J. Harland.
J.M.Masters
The Journal of Pathology Volume 198, Issue 2, October 2002, Pages: 237-244

The comparative values of bone marrow aspirate and trephine for obtaining bone scan-targeted metastases from hormone-refractory prostate cancer.
Brown RS, Dogan A, Ell PJ, Payne HA, Masters JR, Harland SJ.
Prostate Cancer Prostatic Dis. 2002;5(2):144-51

Anal Canal Enhancement on Dynamic Contrast Enhanced MRI after Pelvic Radiotherapy
D Hayne, C Hare, Payne H, Boulos P.
A. Colo Proctology 2003 11: 598-602

Penile preservation in squamous cell carcinoma of the bulbar membranous urethra.
Christopher N, Brown RSD, Araya M, Hayne D, Payne HA, Ralph D.-
British Journal Urology International 2003: 192: 567-572

How do we deal with rising PSA after primary therapy for localised prostate cancer?
Anderson JB, Fourcade RO, Payne HA, Schulman CC.
British Journal of Urology 2003

The Clinical Features of Metastatic Prostate Cancer with Serum Prostatic Antigen (PSA) < 10ng/ml – the “PSA Negative” Patients
Birtle A, Freeman A, Masters J, Harland S, Payne H.
Cancer. 2003 Dec 1;98(11):2362-7.

The use of Misoprostol Suppositories to reduce Radiotherapy induced Anorectal Dysfunction
Kushwaha R, Payne H, Boulos P.
Journal Clinical Oncology 2003

Prostate motion during radiotherapy- an analysis using dose-volume-histogram of the rectal volume in the radiation field
Monkridge D,McCormack M, Payne HA
United Kingdom Radiation Oncology Meeting – Bath 2003

Dose distributions of prostatic radiotherapy using multifield low enery photons arrangements verses conventional 3 field techniques
Payne HA, Russell S, Hughes H.
United Kingdom Radiation Oncology Meeting – Bath 2003

Serum PSA negative metastatic prostate cancer: histopathology and an alternative diagnostic marker
AJ Birtle, A Freeman, JR Masters, HA Payne
Histopathology August 2003.

The immunohistochemical characteristics of patients presenting with metastatic prostate cancer and a serum PSA<10
AJ Birtle, A Freeman, S Harland, H Payne
Accepted publication American Journal of Surgical Pathology September 2003

Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?
AJ Birtle, A Freeman, HA Payne
British journal of Urology International September 2003(92):490-492

Physiological changes of the Anorectum after Pelvic Radiotherapy for the Treatment of Prostate and Bladder Cancer
Rajeev Kushwaha, Dickon Hayne, Caroline Vaizey, Heather Payne, Paul Boulos.
Diseases of the Colon and Rectum 2003: p1182-1188

Bicalutamide 150mg ( Casodex) Significantly Increases the time to Objective Progression when used as Adjuvant Treatment to Radiotherapy – an Analysis of Event Time Ratio.
Payne HA, Tyrell C, Mcleod, See WA, Wirth M, Iversen P, Garside L.
International Journal of Radiation, Oncology, Biology, Physics. 2003 volume 57: 2: 173-175

Patients’ Preference for the management of Non-Metastatic Prostate Cancer: Discrete choice ananlysis.
Sculpher M, Stirling B, Fry P, Payne H, Emberton M
BMJ 2004 328:382-384

Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the Early Prostate Cancer programme at a median 5.4 years' follow-up
Chris J. Tyrrell, Heather Payne, William A. See, David G. McLeod, Manfred P.Wirth, Peter Iversen, Jon Armstrong, Clive Morris, on behalf of the 'Casodex' Early Prostate Cancer Trialists' Group
Radiotherapy and Oncology – September 2004